Aktienanalyse zu Compugen Ltd (CGEN)CGENCompugen Ltd

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

Compugen Ltd (CGEN) is currently trading at $1.98, which is significantly below its 52-week high of $3.23, suggesting potential upside. However, the RSI is at 44.79, indicating that the stock is neither overbought nor oversold, which may suggest a lack of strong momentum. The company has shown a remarkable revenue increase of 4480.3% year-over-year in Q4 2025, but it also reported a net income loss of $7.67 million in Q1 2026. The insider selling has increased by 177.02%, which raises concerns about insider confidence. Given these mixed signals, it may be prudent to hold off on buying until more clarity on profitability and insider sentiment emerges.

2 analysts cover CGEN: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.00.